Peripheral opioid analgesia in experimental human pain models
This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) bec...
Gespeichert in:
Veröffentlicht in: | Brain (London, England : 1878) England : 1878), 2003-05, Vol.126 (5), p.1092-1102 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1102 |
---|---|
container_issue | 5 |
container_start_page | 1092 |
container_title | Brain (London, England : 1878) |
container_volume | 126 |
creator | Tegeder, Irmgard Meier, Silke Burian, Maria Schmidt, Helmut Geisslinger, Gerd Lötsch, Jörn |
description | This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic. |
doi_str_mv | 10.1093/brain/awg115 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73182419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19400777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</originalsourceid><addsrcrecordid>eNqF0M9LHDEUwPFQlLra3nouQ8GeOjUvPycHDyK1KwhaWqX0El5mMxo7v0x20P73Zt1FoRcP4R3y4YV8CfkA9CtQww9cxNAf4P01gHxDZiAULRlItUVmlFJVVkbSHbKb0i2lIDhTb8kOMGUoFWZGDi98DOONj9gWwxiGsCiwx_bap4BF6Av_MGbQ-X6Zwc3UYV-M-b2iGxa-Te_IdoNt8u83c49cnnz7dTwvz86_nx4fnZW10GpZqkoYpz3UUhtWLZDr2glnJGrWOGSce-lWpwbpHG8U4xK8qRomhABEyvfI5_XeMQ53k09L24VU-7bF3g9TsppDxQSYVyEYQanWOsNP_8HbYYr55ysjcyYqV9u-rFEdh5Sib-yYW2D8Z4HaVXz7FN-u42f-cbNzcp1fvOBN7Qz2NwBTjW0Tsa9DenHCMDAVZFeuXUhL__B8j_GvVZpraee__9j51Q8pjVL2J38EgkCcAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195432059</pqid></control><display><type>article</type><title>Peripheral opioid analgesia in experimental human pain models</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</creator><creatorcontrib>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</creatorcontrib><description>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</description><identifier>ISSN: 0006-8950</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awg115</identifier><identifier>PMID: 12690049</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Analgesics - therapeutic use ; Anesthesia ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Cold Temperature - adverse effects ; Cross-Over Studies ; DOMS = delayed onset of muscle soreness ; Double-Blind Method ; Electric Stimulation ; Female ; Humans ; Hyperalgesia - drug therapy ; Hyperalgesia - etiology ; inflammation ; Local anesthesia. Pain (treatment) ; M6G = morphine‐6‐glucuronide ; Male ; Medical sciences ; Morphine ; Morphine Derivatives - therapeutic use ; morphine‐6‐glucuronide ; Muscle Contraction ; pain ; Peripheral Nerves - drug effects ; Peripheral Nerves - metabolism ; peripheral opioid receptor ; Receptors, Opioid - drug effects ; VAS = visual analogue scale</subject><ispartof>Brain (London, England : 1878), 2003-05, Vol.126 (5), p.1092-1102</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) May 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</citedby><cites>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14921981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12690049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tegeder, Irmgard</creatorcontrib><creatorcontrib>Meier, Silke</creatorcontrib><creatorcontrib>Burian, Maria</creatorcontrib><creatorcontrib>Schmidt, Helmut</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><creatorcontrib>Lötsch, Jörn</creatorcontrib><title>Peripheral opioid analgesia in experimental human pain models</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</description><subject>Adult</subject><subject>Analgesics - therapeutic use</subject><subject>Anesthesia</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Cold Temperature - adverse effects</subject><subject>Cross-Over Studies</subject><subject>DOMS = delayed onset of muscle soreness</subject><subject>Double-Blind Method</subject><subject>Electric Stimulation</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperalgesia - drug therapy</subject><subject>Hyperalgesia - etiology</subject><subject>inflammation</subject><subject>Local anesthesia. Pain (treatment)</subject><subject>M6G = morphine‐6‐glucuronide</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Morphine</subject><subject>Morphine Derivatives - therapeutic use</subject><subject>morphine‐6‐glucuronide</subject><subject>Muscle Contraction</subject><subject>pain</subject><subject>Peripheral Nerves - drug effects</subject><subject>Peripheral Nerves - metabolism</subject><subject>peripheral opioid receptor</subject><subject>Receptors, Opioid - drug effects</subject><subject>VAS = visual analogue scale</subject><issn>0006-8950</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0M9LHDEUwPFQlLra3nouQ8GeOjUvPycHDyK1KwhaWqX0El5mMxo7v0x20P73Zt1FoRcP4R3y4YV8CfkA9CtQww9cxNAf4P01gHxDZiAULRlItUVmlFJVVkbSHbKb0i2lIDhTb8kOMGUoFWZGDi98DOONj9gWwxiGsCiwx_bap4BF6Av_MGbQ-X6Zwc3UYV-M-b2iGxa-Te_IdoNt8u83c49cnnz7dTwvz86_nx4fnZW10GpZqkoYpz3UUhtWLZDr2glnJGrWOGSce-lWpwbpHG8U4xK8qRomhABEyvfI5_XeMQ53k09L24VU-7bF3g9TsppDxQSYVyEYQanWOsNP_8HbYYr55ysjcyYqV9u-rFEdh5Sib-yYW2D8Z4HaVXz7FN-u42f-cbNzcp1fvOBN7Qz2NwBTjW0Tsa9DenHCMDAVZFeuXUhL__B8j_GvVZpraee__9j51Q8pjVL2J38EgkCcAA</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Tegeder, Irmgard</creator><creator>Meier, Silke</creator><creator>Burian, Maria</creator><creator>Schmidt, Helmut</creator><creator>Geisslinger, Gerd</creator><creator>Lötsch, Jörn</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20030501</creationdate><title>Peripheral opioid analgesia in experimental human pain models</title><author>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Analgesics - therapeutic use</topic><topic>Anesthesia</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Cold Temperature - adverse effects</topic><topic>Cross-Over Studies</topic><topic>DOMS = delayed onset of muscle soreness</topic><topic>Double-Blind Method</topic><topic>Electric Stimulation</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperalgesia - drug therapy</topic><topic>Hyperalgesia - etiology</topic><topic>inflammation</topic><topic>Local anesthesia. Pain (treatment)</topic><topic>M6G = morphine‐6‐glucuronide</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Morphine</topic><topic>Morphine Derivatives - therapeutic use</topic><topic>morphine‐6‐glucuronide</topic><topic>Muscle Contraction</topic><topic>pain</topic><topic>Peripheral Nerves - drug effects</topic><topic>Peripheral Nerves - metabolism</topic><topic>peripheral opioid receptor</topic><topic>Receptors, Opioid - drug effects</topic><topic>VAS = visual analogue scale</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tegeder, Irmgard</creatorcontrib><creatorcontrib>Meier, Silke</creatorcontrib><creatorcontrib>Burian, Maria</creatorcontrib><creatorcontrib>Schmidt, Helmut</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><creatorcontrib>Lötsch, Jörn</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tegeder, Irmgard</au><au>Meier, Silke</au><au>Burian, Maria</au><au>Schmidt, Helmut</au><au>Geisslinger, Gerd</au><au>Lötsch, Jörn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral opioid analgesia in experimental human pain models</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>126</volume><issue>5</issue><spage>1092</spage><epage>1102</epage><pages>1092-1102</pages><issn>0006-8950</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12690049</pmid><doi>10.1093/brain/awg115</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-8950 |
ispartof | Brain (London, England : 1878), 2003-05, Vol.126 (5), p.1092-1102 |
issn | 0006-8950 1460-2156 |
language | eng |
recordid | cdi_proquest_miscellaneous_73182419 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
subjects | Adult Analgesics - therapeutic use Anesthesia Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Cold Temperature - adverse effects Cross-Over Studies DOMS = delayed onset of muscle soreness Double-Blind Method Electric Stimulation Female Humans Hyperalgesia - drug therapy Hyperalgesia - etiology inflammation Local anesthesia. Pain (treatment) M6G = morphine‐6‐glucuronide Male Medical sciences Morphine Morphine Derivatives - therapeutic use morphine‐6‐glucuronide Muscle Contraction pain Peripheral Nerves - drug effects Peripheral Nerves - metabolism peripheral opioid receptor Receptors, Opioid - drug effects VAS = visual analogue scale |
title | Peripheral opioid analgesia in experimental human pain models |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A01%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20opioid%20analgesia%20in%20experimental%20human%20pain%20models&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Tegeder,%20Irmgard&rft.date=2003-05-01&rft.volume=126&rft.issue=5&rft.spage=1092&rft.epage=1102&rft.pages=1092-1102&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/awg115&rft_dat=%3Cproquest_cross%3E19400777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195432059&rft_id=info:pmid/12690049&rfr_iscdi=true |